BGBIO Stock Overview A clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. More details
Rewards Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
BerGenBio ASA Competitors Price History & Performance
Summary of share price highs, lows and changes for BerGenBio Historical stock prices Current Share Price NOK 8.35 52 Week High NOK 35.80 52 Week Low NOK 5.62 Beta 1.53 1 Month Change -16.32% 3 Month Change -20.70% 1 Year Change -65.64% 3 Year Change -99.59% 5 Year Change -99.65% Change since IPO -99.67%
Recent News & Updates
BerGenBio ASA, Annual General Meeting, May 20, 2025 Dec 16 BerGenBio ASA to Report Q4, 2025 Results on Feb 19, 2026
BerGenBio ASA Appoints Olav Hellebø as CEO, Effective November 21, 2024 Nov 21
New major risk - Share price stability Nov 19
Martin Olin to Step Down from BerGenBio ASA as CEO Oct 11
BerGenBio ASA Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients Oct 07 See more updates
BerGenBio ASA, Annual General Meeting, May 20, 2025 Dec 16 BerGenBio ASA to Report Q4, 2025 Results on Feb 19, 2026
BerGenBio ASA Appoints Olav Hellebø as CEO, Effective November 21, 2024 Nov 21
New major risk - Share price stability Nov 19
Martin Olin to Step Down from BerGenBio ASA as CEO Oct 11
BerGenBio ASA Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients Oct 07
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans? Sep 21
Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky Jun 02
BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients Dec 16
BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting Dec 11 BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million. Dec 08
Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely Dec 07
New major risk - Financial position Nov 17 BerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025
BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer Oct 23
BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely Aug 24
Price target decreased by 63% to kr5.68 Aug 23
New major risk - Shareholder dilution Jun 15 BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million. Jun 15
Chief Executive Officer exercised options to buy kr323k worth of stock. Jun 12
BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO Jun 07
BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors May 23
BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023 May 10
High number of new and inexperienced directors Mar 01
BerGenBio ASA Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients Feb 16
BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely Feb 06
BerGenBio ASA Announces Board Appointments Feb 02 BerGenBio ASA to Report Q3, 2023 Results on Nov 14, 2023
Price target decreased to kr12.00 Nov 16
BerGenBio ASA Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations Oct 11
BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Platform for Hospitalized Covid-19 Patients Sep 28
Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely? Sep 26
BerGenBio ASA Provides Update on Clinical Development Aug 23
Chairman of the Board recently bought kr268k worth of stock Jun 18
Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely? Jun 11
Consensus forecasts updated Jun 03
Price target decreased to kr47.50 May 05
BerGenBio ASA Announces Complete Data Analysis of Accord2 Phase II Bemcentinib Study in Hospitalized Covid-19 Patients - Primary Efficacy Endpoint Met Apr 26
Bergenbio Presents Bemcentinib Covid-19 Clinical Trial Data At Eccmid 2022 Apr 25
BerGenBio ASA Appoints Cristina Oliva as Chief Medical Officer, Effective April 25, 2022 Apr 11
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans? Feb 17
High number of new and inexperienced directors Feb 02
Chief Executive Officer recently bought kr204k worth of stock Jan 11
We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate Sep 21
BerGenBio ASA Completes Recruitment of Phase II AML Study ((BGBC003) Sep 08
Chief Executive Officer Richard Godfrey has left the company Aug 26
BerGenBio ASA Presents Encouraging Combined Data for Bemcentinib from Two Phase II Covid-19 Studies At Eccmid Jul 14
BerGenBio ASA Updates Preliminary Survival Data from the Ongoing Phase II Study of Bemcentinib Jun 12 BerGenBio ASA Receives Food and Drug Administration Fast Track Designation for Bemcentinib / Anti-Pd-(L)1 Combination in NSCLC
BerGenBio ASAPresents Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC Jun 05
BerGenBio ASA to Present Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC at ASCO Meeting May 21
BerGenBio ASA Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised Covid-19 Patients May 18
BerGenBio ASA Announces Pre-Clinical COVID-19 Data Presented at Virtual Immunology 2021 May 12
It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year Mar 13
BerGenBio ASA Completes Enrolment into Latest Cohort of Phase II Bemcentinib Combination Study in Refractory NSCLC Mar 12
BerGenBio ASA Announces Start of Phase 1B Trial of Anti-AXL Antibody Tilvestamab (BGB149) Mar 06
BerGenBio ASA Closes Recruitment into Trial Assessing Bemcentinib in Covid-19 Patients Mar 05
New 90-day low: kr30.75 Mar 01
Analysts update estimates Feb 17
We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow Feb 11
Revenue and earnings in line with expectations Feb 11
BerGenBio ASA Announces Second Data Monitoring Committee Recommends Continuation of Bergenbio's BGBC020 Trial Assessing Bemcentinib in COVID-19 Patients Feb 08
Price target raised to kr63.00 Feb 03
BerGenBio ASA Presents an Update from Its Phase II Study of Bemcentinib in Combination with Anti-PD-1 Therapy Pembrolizumab (Bgbc008) Jan 29
Bergenbio to Present Updates from Ongoing Phase II Bemcentinib Combination Study in Refractory NSCLC At WCLC 2020 Jan 14
New 90-day high: kr37.30 Jan 11
BerGenBio ASA to Report Q4, 2020 Results on Feb 10, 2021 Dec 26 BerGenBio ASA to Report Q3, 2021 Results on Nov 16, 2021
What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)? Dec 21
New 90-day high: kr36.00 Dec 16
BerGenBio ASA Presents Updated Clinical Data from Two Phase II Studies of Bemcentinib in AML and MDS Patients at ASH 2020 Dec 09
BerGenBio ASA Confirms First Patient Enrolled in Phase II Trial Assessing Bemcentinib as Potential Treatment for COVID-19 in India Nov 25
Earnings beat expectations Nov 19
BerGenBio ASA Presents Phase II Bemcentinib Combination Study in NSCLC At Annual SITC Meeting Nov 12
New 90-day low: kr28.20 Oct 22
BerGenBio ASA to Present Clinical Translational Data from the Ongoing Phase II Bemcentinib Combination Study in NSCLC At Annual SITC Meeting Oct 15
BerGenBio Presents Data on Anti-Axl Antibody Tilvestamab Oct 14
BerGenBio Announces First Patient Dosed with Bemcentinib in Relapsed Malignant Pleural Mesothelioma Investigator Sponsored Phase IIa Study Oct 07 Shareholder Returns BGBIO NO Biotechs NO Market 7D -9.4% -3.9% -2.8% 1Y -65.6% -73.8% -0.8%
See full shareholder returns
Return vs Market: BGBIO underperformed the Norwegian Market which returned -0.8% over the past year.
Price Volatility Is BGBIO's price volatile compared to industry and market? BGBIO volatility BGBIO Average Weekly Movement 19.1% Biotechs Industry Average Movement 14.0% Market Average Movement 5.0% 10% most volatile stocks in NO Market 10.9% 10% least volatile stocks in NO Market 2.6%
Stable Share Price: BGBIO's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: BGBIO's weekly volatility has increased from 13% to 19% over the past year.
About the Company BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors.
Show more BerGenBio ASA Fundamentals Summary How do BerGenBio's earnings and revenue compare to its market cap? BGBIO fundamental statistics Market cap NOK 326.38m Earnings (TTM ) -NOK 152.29m Revenue (TTM ) NOK 521.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BGBIO income statement (TTM ) Revenue NOK 521.00k Cost of Revenue NOK 0 Gross Profit NOK 521.00k Other Expenses NOK 152.81m Earnings -NOK 152.29m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 26, 2025
Earnings per share (EPS) -3.90 Gross Margin 100.00% Net Profit Margin -29,230.13% Debt/Equity Ratio 0%
How did BGBIO perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 01:21 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources BerGenBio ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ulrik Trattner Carnegie Investment Bank AB Patrik Ling DNB Markets Geir Holom DNB Markets
Show 2 more analysts 
